Stockholders Approve New Equity Incentive Plan and Expanded ESPP

summarizeSummary

Celcuity stockholders approved a new equity incentive plan and an expanded employee stock purchase plan, authorizing over 3.2 million additional shares for future issuance.

check_boxKey Events · Corporate Governance and Compliance · CELC

• 2026 Stock Incentive Plan Approved

  Stockholders approved the 2026 Stock Incentive Plan, authorizing the company to issue up to 3,000,000 shares of common stock for equity awards to employees, consultants, and non-employee directors. This plan replaces the 2017 plan, under which no further awards will be made.

• Employee Stock Purchase Plan Expanded

  The Amended and Restated 2017 Employee Stock Purchase Plan (ESPP) was approved, increasing the number of shares available for issuance by 289,199 and extending its expiration date by ten years.

• Potential Dilution

  In total, these approvals authorize the potential issuance of 3,289,199 new shares, which represents a significant amount of potential dilution if all shares are issued.

• Routine Annual Meeting Approvals

  Stockholders also re-elected eight directors, ratified the appointment of Boulay PLLP as the independent auditor, and approved executive officer compensation on an advisory basis.

auto_awesomeAnalysis · CELC · Industrial Applications And Services

Celcuity's stockholders approved a new 2026 Stock Incentive Plan, authorizing the potential issuance of 3,000,000 shares, and an amendment to the 2017 Employee Stock Purchase Plan (ESPP), adding 289,199 shares. While these plans are crucial for attracting and retaining talent, especially for a biotech company with recent positive clinical trial results and FDA Priority Review, the authorization of over 3.2 million new shares represents a substantial potential dilution for existing shareholders. This is a standard corporate governance action, but the magnitude of shares authorized makes it an important event.